Integrated radiosurgical treatment of resectable pancreatic head carcinoma

被引:5
|
作者
Crucitti, F
Doglietto, GB
Frontera, D
Viola, G
Morganti, AG
Valentini, V
Alfonsi, G
Trodella, L
Cellini, N
机构
[1] Catholic Univ, Sch Med, Dept Surg, I-00168 Rome, Italy
[2] Catholic Univ, Sch Med, Dept Radiotherapy, I-00168 Rome, Italy
关键词
pancreatic carcinoma; surgical resection; intraoperative radiotherapy;
D O I
10.1097/00006676-199801000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Thirty-six patients with pancreatic head carcinoma entered a protocol, but only 20 were suitable for resection and evaluation of long-term survival. They were nine males and 11 females, with a mean age of 64.3 years. Following surgical resection, 10 Gy was delivered to the tumor bed intraoperatively. Postoperative radiotherapy was performed 4-6 weeks after surgery: patients were treated with 50.4 Gy (1.8 Gy/day, 5 days/week) to the tumor and nodal bed. Since 1991, 10 patients have also received preoperative short-course radiotherapy (5 Gy) of the liver and pancreas. Postoperative morbidity was 25%; two postoperative deaths were observed in patients with locally advanced neoplasms, in whom a vascular resection was also performed. Only 14 patients started postoperative radiotherapy, which was interrupted in two cases. At present, 14 patients are dead and four are alive and disease free. The local recurrence rate was 11.1% and distant metastases were observed in 66.7% of cases. The median actuarial survival was 11.9 months, but it was 18.5 months in patients with disease-free resection margins. A significantly better survival was also observed in patients submitted to short-course preoperative radiotherapy. These preliminary results show that intraoperative and perioperative radiotherapy is feasible and may improve local control of disease. Unfortunately, these results are not matched by a significant improvement in survival due to the high incidence of intraabdominal metastases. Thus, new therapeutic modalities, including preoperative radiotherapy (with or without chemotherapy), should be tested.
引用
收藏
页码:31 / 39
页数:9
相关论文
共 50 条
  • [31] Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer
    Scheufele, F.
    Friess, H.
    CHIRURG, 2020, 91 (05): : 391 - 395
  • [32] Treatment of Borderline Resectable Pancreatic Cancer
    Cooper, Amanda B.
    Tzeng, Ching-Wei D.
    Katz, Matthew H. G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (03) : 293 - 310
  • [33] Adjuvant treatment for resectable pancreatic cancer
    Chua, YJ
    Cunningham, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (20) : 4532 - 4537
  • [34] Trends in the Treatment of Resectable Pancreatic Adenocarcinoma
    Siavash Raigani
    John Ammori
    Julian Kim
    Jeffrey M. Hardacre
    Journal of Gastrointestinal Surgery, 2014, 18 : 113 - 123
  • [35] Neoadjuvant treatment for resectable pancreatic adenocarcinoma
    Wong, John
    Solomon, Naveenraj L.
    Hsueh, Chung-Tsen
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2016, 7 (01): : 1 - 8
  • [36] Radiotherapeutic strategies in the multimodality approach of resectable and non-resectable pancreatic carcinoma
    Wiegel, T
    Runkel, N
    Frommhold, H
    Rübe, C
    Hinkelbein, W
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (07) : 299 - 306
  • [37] A new technique of gastroenterostomy for palliative treatment of pancreatic head carcinoma
    Machado, MCC
    Cunha, JEM
    Penteado, S
    Jukemura, J
    Herman, P
    Bacchella, T
    HEPATO-GASTROENTEROLOGY, 2000, 47 (36) : 1741 - 1743
  • [38] Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
    Heinemann, V.
    Haas, M.
    Boeck, S.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2484 - 2492
  • [39] Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer
    Neoptolemos, John P.
    Ghaneh, Paula
    Hackert, Thilo
    HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10 (05) : 714 - 716
  • [40] Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Satoi, S.
    Yamamoto, T.
    Uchida, K.
    Fujii, T.
    Kin, T.
    Asano, T.
    Hanada, K.
    Itoi, T.
    Murakami, Y.
    Igarashi, H.
    Eguchi, H.
    Kuroki, T.
    Shimizu, Y.
    Tani, M.
    Tanno, S.
    Tsuji, Y.
    Hirooka, Y.
    Masamune, A.
    Mizumoto, K.
    Shimokawa, T.
    Yamaue, H.
    Okazaki, K.
    PANCREAS, 2019, 48 (10) : 1516 - 1517